Impact and effectiveness of rotateq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland

Pediatric Infectious Disease Journal

Volumn 32, Issue 12, 2013, Pages 1365-1373

  Vesikari, Timo ^a   Uhari, Matti ^b   Renko, Marjo ^b   Hemming, Maria ^a   Salminen, Marjo ^a   Torcel Pagnon, Laurence ^c   Bricout, Hélène ^c   Simondon, François ^c  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c SANOFI PASTEUR   (France)

Author keywords

Finland; Gastroenteritis; Impact; Rotavirus; Vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE;

ACUTE GASTROENTERITIS; ADOLESCENT; ARTICLE; CATCHMENT; CHILD; CONFIDENCE INTERVAL; DATA BASE; DISEASE SURVEILLANCE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; GENOTYPE; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNIZATION; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAVIRUS; ROTAVIRUS INFECTION; SCHOOL CHILD; GASTROENTERITIS; HEALTH SURVEY; IMMUNOLOGY; INFANT; PREVENTIVE HEALTH SERVICE; PROSPECTIVE STUDY; ROTAVIRUS INFECTIONS; VIROLOGY;

CHILD, PRESCHOOL; FEMALE; FINLAND; GASTROENTERITIS; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MALE; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 84891746571     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000086     Document Type: Article

References (39)

1. Tate JE, Burton AH, Boschi-Pinto C, et al.; Who-coordinated global rotavirus surveillance network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136-141.
2. Soriano-Gabarró M, Mrukowicz J, Vesikari T, et al. Burden of rotavi-rus disease in european Union countries. Pediatr Infect Dis J. 2006;25(1 suppl):s7-s11.
3. Van Der Wielen M, Giaquinto C, Gothefors L, et al.; Reveal study group. Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the ReVeaL study. BMC Fam Pract. 2010;11:22.
4. Diez Domingo J, Patrzalek M, Cantarutti L, et al. The impact of childhood acute rotavirus gastroenteritis on the parents' quality of life: prospective observational study in european primary care medical practices. BMC Pediatr. 2012;12:58.
5. Vesikari T, Van Damme P, Giaquinto C, et al. European society for paediatric infectious Diseases/european society for paediatric Gastroenterology, Hepatology, and nutrition evidence-based recommendations for rotavirus vaccination in europe. J Pediatr Gastroenterol Nutr. 2008;46 (suppl 2):s38-s48.
6. Vesikari T, Mäki M, Sarkkinen HK, et al. Rotavirus, adenovirus, and non-viral enteropathogens in diarrhoea. Arch Dis Child. 1981;56:264-270.
7. Mäki M. a prospective clinical study of rotavirus diarrhoea in young children. Acta Paediatr Scand. 1981;70:107-113.
8. Vesikari T, Rautanen T, Von BONSDORFF CH. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl. 1999;88:24-30.
9. Vesikari T, Isolauri E, D'HONDT E, et al. Protection of infants against rota-virus diarrhoea by Rit 4237 attenuated bovine rotavirus strain vaccine. Lancet. 1984;1:977-981.
10. Vesikari T, Isolauri E, Delem A, et al. Clinical effcacy of the Rit 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr. 1985;107:189-194.
11. Vesikari T. Rotavirus vaccine studies in europe. Acta Paediatr Suppl. 1999;88:9-13.
12. Joensuu J, Koskenniemi E, Pang XL, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997;350:1205-1209.
13. Vesikari T, Matson DO, Dennehy P, et al.; Rotavirus effcacy and safety trial (rest) study team. Safety and effcacy of a pentavalent human-bovine (Wc3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33.
14. Vesikari T, Karvonen A, Prymula R, et al. Effcacy of human rotavirus vaccine against rotavirus gastroenteritis during the frst 2 years of life in european infants: randomised, double-blind controlled study. Lancet. 2007;370:1757-1763.
15. Räsänen S, Lappalainen S, Halkosalo A, et al. Rotavirus gastroenteritis in Finnish children in 2006-2008, at the introduction of rotavirus vaccination. Scand J Infect Dis. 2011;43:58-63.
16. Nohynek H, Salo H, Renko M, et al. Finland introduces rotavirus vaccine into the national vaccination programme in september 2009. Euro Surveill. 2009;14:pii:19322.
17. Hemming M, Vesikari T. Vaccine-derived human-bovine double reassor-tant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J. 2012;31:992-994.
18. Statistics Finland. population. 2011. available at: http://www.stat.f/ til/vrm en.html. accessed september 7, 2012
19. National institute for health and welfare (THL). Health and well-being inequalities among children and their families. national institute for health and wellfare (tHL) Report 16/2012 [in Finnish]. available at: http://www. thl.f/enUs/web/en. accessed september 7, 2012.
20. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavi-rus vaccine in a large urban population in the United states. Pediatrics. 2010;125:e199-e207.
21. Castilla J, Beristain X, Martínez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in navarre, spain. Vaccine. 2012;30:539-543.
22. Field EJ, Vally H, Grimwood K, et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in australia. Pediatrics. 2010;126:e506-e512.
23. Gagneur A, Nowak E, Lemaitre T, et al.; Ivanhoe investigators. Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: the iVanHoe study. Vaccine. 2011;29:3753-3759.
24. Guh AY, Hadler JL. Use of the state immunization information system to assess rotavirus vaccine effectiveness in connecticut, 2006-2008. Vaccine. 2011;29:6155-6158.
25. Martinón-Torres F, Bouzón Alejandro M, Redondo Collazo L, et al.; Rotacost research team. Effectiveness of rotavirus vaccination in spain. Hum Vaccin. 2011;7:757-761.
26. Staat MA, Payne DC, Donauer S, et al.; New vaccine surveillance network (NVSN). Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128:e267-e275.
27. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rota-virus vaccine in preventing gastroenteritis in the United states. Pediatrics. 2010;125:e208-e213.
28. Vesikari T, Karvonen A, Ferrante SA, et al. Sustained effcacy of the pen-tavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr Infect Dis J. 2010;29:957-963.
29. World health organization. Generic protocol for monitoring impact of rota-virus vaccination on gasteroenteritis disease burden and viral strains. 2008. available at: http://www.who.int/nuvi/rotavirus/WHoiVB08.16eng. pdf. accessed March 27, 2013.
30. Iturriza-Gómara M, Dallman T, Bányai K, et al. Rotavirus genotypes co-circulating in europe between 2006 and 2009 as determined by euroRotanet, a pan-european collaborative strain surveillance network. Epidemiol Infect. 2011;139:895-909.
31. Centers for disease control and prevention (CDC). Reduction in rotavi-rus after vaccine introduction-United states, 2000-2009. MMWR Morb Mortal Wkly Rep. 2009;58:1146-1149.
32. Hanquet G, Ducoffre G, Vergison A, et al. Impact of rotavirus vaccination on laboratory confrmed cases in Belgium. Vaccine. 2011;29:4698-4703.
33. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of Us rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124:465-471.
34. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine. 2010;28:7507-7513.
35. Leino T, Ollgren J, Salo H, et al. First year experience of rotavirus immunisation programme in Finland. Vaccine. 2012;31:176-182.
36. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among Us children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 Us states. J Infect Dis. 2010;201:1617-1624.
37. Giaquinto C, Dominiak-Felden G, Van Damme P, et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rota-virus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin. 2011;7:734-748.
38. Hemming M, Räsänen S, Huhti L, et al. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of Rotateq vaccine into the national immunization programme in Finland. Eur J Pediatr. 2013;172:739-746.
39. Lopman BA, Curns AT, Ye N C, et al. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United states. J Infect Dis. 2011;204:980-986.